Kanagawa, Japan

Aiko Miyata


Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1995-1996

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Aiko Miyata: Innovator in Antimicrobial Research

Introduction

Aiko Miyata is a prominent inventor based in Kanagawa, Japan. She has made significant contributions to the field of antimicrobial research, particularly through her innovative work on macrolide derivatives. With a total of 2 patents to her name, her inventions are paving the way for advancements in pharmaceutical applications.

Latest Patents

Miyata's latest patents focus on 16-membered macrolide derivatives and the processes for producing them. These derivatives are represented by a specific chemical formula, where various groups are defined to enhance their antimicrobial properties. The compounds exhibit excellent and long-acting antimicrobial activities, making them valuable in medical applications. A novel process for producing these derivatives has also been disclosed, showcasing her innovative approach to pharmaceutical development.

Career Highlights

Aiko Miyata is currently associated with Meiji Seika Kaisha, Ltd., a company known for its commitment to research and development in the pharmaceutical industry. Her work has not only contributed to the company's portfolio but has also advanced the field of antimicrobial research significantly.

Collaborations

Miyata has collaborated with notable colleagues such as Keiichi Ajito and Ken-ichi Kurihara. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Aiko Miyata's contributions to antimicrobial research through her innovative patents highlight her role as a leading inventor in her field. Her work continues to influence the development of effective pharmaceutical solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…